Fycompa® (perampanel) – Expanded indication
July 26, 2017 – Eisai announced the FDA approval of Fycompa (perampanel) as monotherapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
Download PDF
